MedTrace Logo

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

NCT00080080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-06-08

No results posted yet for this study

Summary

The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.

Conditions

Interventions

DRUG

talabostat (PT-100) tablets

DRUG

Docetaxel

Sponsors & Collaborators

  • Point Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080080 on ClinicalTrials.gov